...
首页> 外文期刊>Clinical Chemistry >A Novel FMR1 PCR Method for the Routine Detection of Low Abundance Expanded Alleles and Full Mutations in Fragile X Syndrome
【24h】

A Novel FMR1 PCR Method for the Routine Detection of Low Abundance Expanded Alleles and Full Mutations in Fragile X Syndrome

机译:一种新型FMR1 PCR方法,用于常规检测脆性X综合征的低丰度扩展等位基因和全突变

获取原文
获取原文并翻译 | 示例
           

摘要

Fragile X syndrome (FXS) is a trinucleotide-repeat disease caused by the expansion of CGG sequences in the 5' untranslated region of the FMR1 (fragile X mental retardation 1) gene. Molecular diagnoses of FXS and other emerging FMR1 disorders typically rely on 2 tests, PCR and Southern blotting; however, performance or throughput limitations of these methods currently constrain routine testing. We evaluated a novel FMR1 gene-specific PCR technology with DNA templates from 20 cell lines and 146 blinded clinical samples. The CGG repeat number was determined by fragment sizing of PCR amplicons with capillary electrophoresis, and results were compared with those for FMR1 Southern blotting analyses with the same samples. The FMR1 PCR accurately detected full-mutation alleles up to at least 1300 CGG repeats and consisting of >99% GC character. All categories of alleles detected by Southern blotting, including 66 samples with full mutations, were also identified by the FMR1 PCR for each of the 146 clinical samples. Because all full mutation alleles in samples from heterozygous females were detected by the PCR, allele zygosity was reconciled in every case. The PCR reagents also detected a 1% mass fraction of a 940-CGG allele in a background of 99% 23-CGG allele-a roughly 5- fold greater sensitivity than obtained with Southern blotting. The novel PCR technology can accurately categorize the spectrum of FMR1 alleles, including alleles previously considered too large to amplify; reproducibly detect low abundance full mutation alleles; and correctly infer homozygosity in female samples, thus greatly reducing the need for sample reflexing to Southern blotting.
机译:脆性X综合征(FXS)是由CMR序列在FMR1(脆性X智力低下1)基因的5'非翻译区扩展引起的三核苷酸重复疾病。 FXS和其他新出现的FMR1疾病的分子诊断通常依赖于2种测试,即PCR和Southern印迹;但是,这些方法的性能或吞吐量限制目前限制了常规测试。我们用来自20个细胞系和146个盲临床样品的DNA模板评估了一种新颖的FMR1基因特异性PCR技术。通过毛细管电泳PCR扩增子的片段大小确定CGG重复数,并将结果与​​相同样品的FMR1 Southern印迹分析结果进行比较。 FMR1 PCR可以准确检测到至少1300个CGG重复序列的全突变等位基因,并且具有> 99%的GC特征。还通过FMR1 PCR对146个临床样品中的每个样品进行了Southern印迹检测到的所有类别的等位基因,包括66个具有完整突变的样品。因为通过PCR检测了来自杂合子雌性样品中的所有全突变等位基因,所以在每种情况下都可以调节等位基因的接合性。 PCR试剂还在99%23-CGG等位基因的背景中检测到1%质量分数的940-CGG等位基因-灵敏度比Southern印迹法高约5倍。新颖的PCR技术可以准确地对FMR1等位基因的光谱进行分类,包括先前认为太大而无法扩增的等位基因;可重现地检​​测低丰度全突变等位基因;并正确推断女性样品中的纯合子,从而大大减少了样品反射到Southern印迹的需要。

著录项

  • 来源
    《Clinical Chemistry》 |2010年第3期|p.399-408|共10页
  • 作者单位

    Stela Filipovic-Sadic,1 Sachin Sah,1 Liangjing Chen,1 Julie Krosting,1 Edward Sekinger,1 Wenting Zhang,2,3 Paul J. Hagerman,2,3 Timothy T. Stenzel,1 Andrew G. Hadd,1 Gary J. Latham,1* and Flora Tassone2,31 Diagnostic Research & Technology Development, Asuragen, Inc., Austin, TX, 2 Department of Biochemistry and Molecular Medicine, University of California, School of Medicine, Davis, CA, 3 M.I.N.D. Institute, University of California Davis Medical Center, Sacramento, CA.* Address correspondence to this author at: Asuragen, Inc., 2150 Woodward St., Austin, TX 78744. Fax 512-681-5201, e-mail glatham@asuragen.com.Received September 8, 2009, accepted December 7, 2009.Previously published online at DOI: 10.1373/clinchem.2009.136101Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data, (b) drafting or revising the article for intellectual content, and (c) final approval of the published article.Authors' Disclosures of Potential Conflicts of Interest: Upon manuscript submission, all authors completed the Disclosures of Potential Conflict of Interest form. Potential conflicts of interest:Employment or Leadership: S. Filipovic-Sadic, S. Sah, L. Chen, J. Krosting, T.T. Stenzel, A.G. Hadd, and G.J. Latham, Asuragen.Consultant or Advisory Role: P.J. Hagerman, National Fragile X Foundation (self and immediate family member), Asuragen, Novartis (immediate family member), and Roche (immediate family member).Stock Ownership: S. Filipovic-Sadic, S. Sah, L. Chen, J. Krosting, T.T. Stenzel, G.J. Latham, and A.G. Hadd, Asuragen.Honoraria: P.J. Hagerman, 2008 4th Annual Advances in Neurology Conference (Houston, TX), 2009 McMaster University external thesis reader, 2008 Muscular Dystrophy Society international meeting (faculty stipend), Elsevier Journal of Molecular Biology editorial board (manuscript-handling fees), University of California San Francisco talk (March 2009), University of California San Francisco talk (2009, immediate family member), Institute for Basic Research talk (Staten Island, NY, immediate family member), and University of North Carolina talk (2009, immediate family member).Research Funding: P.J. Hagerman, Neuropharm (immediate family member), Seaside Therapeutics (immediate family member), Coleman Institute (immediate family member), National Fragile X Foundation (self and immediate family member), and NIH (self and immediate family member). This project was supported in part by awards from the Eunice Kennedy Shriver National Institute of Child Health & Human Development, including R43HD060450 to A.G. Hadd, HD044410 to F. Tassone, and HD040661 to P.J. Hagerman.Expert Testimony: P.J. Hagerman, Mullin and Obstetrix case (fragile X testing, immediate family member).Other Remuneration: P.J. Hagerman, Seaside Therapeutics (immediate family member), Roche (immediate family member), Novartis (immediate family member), New Orleans Human Development Center Institute, Movement Disorder Society 12th International Congress, Colorado Clinical Scholars Seminar, Nanomedicine Workshop, Nanomedicine Retreat, Washington University Brain Awareness Week,XLMRMeeting (Brazil), and University of California San Francisco Memory and Aging Center.Role of Sponsor: The funding organizations played a direct role in the design of the study, in the review and interpretation of data, and in the preparation and final approval of the manuscript.Acknowledgments: We thank the patients and their relatives for their participation in this study. F. Tassone dedicates this work to the memory of Matteo.Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health & Human Development or the National Institutes of Health.,;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号